

第30回ICH即時報告会

Q7: 原薬GMP Q&A


Q7 IWG現在までの状況

- ▶ 第1回対面会議：San Diego (2012/11/12～15)
 - Working Process
 - Discrimination Criteria
 - Existing Q&As: PIC/S Expert Circle, WHO, 日本
 - Survey: 実施の決定～様式 ⇒ 各極で実施
- ▶ 第2回対面会議：Brussels (2013/6/3～6)
 - 実施したSurvey結果のまとめ～Q&A候補絞り込み
 - 大阪会議までの課題確定 (Scope; EU, Supply chain; US, Containment & Control; JP/Asia)
- ▶ 第3回目対面会議：大阪 (2014/11/11～14)
 - 32件のQ&A合意 ⇒ EU, US, Asia teamで会議後レビュー: 1st Set
 - 会議後にPIC/SからQ&A提供 ⇒ 大阪会議で合意しなかったものを含めて、各チームでレビュー: 2nd Set

ICH Q7-IWG


Working Process to the ICH Q7 Q&A

Minneapolis focus



Based on the endorsed ICH San Diego Nov. 2012

Work Plan Proposal (IWG最終日)



ミネアポリス会議結果

▶ Q&A

- 1st Set Q&A(23件):レビュー完了せず ➡ リスボンで継続
- 2nd Set Q&A(34件):ミネアポリス後チームで評価

▶ Public consultation ➡ 実施しない

- Q7ガイドラインの規定の範囲を越えていない(=新たな要件を作成していない)
- スケジュールに影響


▶ リスボン対面会議を実施

- 11月10日~13日

▶ リスボン会議以降継続の可能性

影響

- ▶ Q&A作成のコンセプト
 - Q7 IWGの目的
 - Discrimination Criteria



Guiding Principles for the ICH Q7 Q&A

- **Potential discrimination criteria for Q&As**


The Q&A should **NOT**:

- Explain 'How to do'
- Restate the text from ICH Q7
- Enlarge scope of ICH Q7
- Address too specific questions
- Establish new requirement
- Address regional matters
- Be outdated, no longer relevant
- Be included, if better handled in a training environment

Items	Keywords
Scope	– Steps before defined SM, – Classical fermentation and biotech. (後述), – Replacing original labels
Quality Management	– QU independent from production, – PQR vs. trend analysis, – Quality defect vs. complaint, – Recalls
Training	– Periodic assessment of training
Containment	– Risk based approach (後述)
Validation	– Lifecycle approach of PV, – Source change, – Dedicated equipment vs. visually clean, – Equipment cleaning time limits vs. cleaning validation
Materials Management	– Appropriate spec. before blending, – Evaluation of suppliers
Laboratory Controls	– Extend API's retest date, – Use of more protective packaging system, – Impurity profiles for APIs from herbal or animal tissue origin
Supplier Management	– Responsibility of consultants, – Subcontracting, – Outsource activities
Supply Chain Management	– Transferring to another unit under the company's control

注) 抜粋: IWGで検討中であり、確定ではない。

Applicability to Biologicals/biotech and relationship with Q5D



注) IWGで検討中であり、確定ではない。

Containment Q&A (Draft)

The principles of QRM [ICH Q9, Annex II.4] should be applied for control of and during design of buildings and facilities for the purpose of containment, taking into consideration the pharmacological / toxicological / chemical / biological properties of the API, intermediate and/or raw material to be handled or manufactured.

Appropriate containment measures and controls [ICH Q7, 4.42] include but are not limited to the following:

- Technical controls - e.g., dedicated production areas, closed / dedicated HVAC system, closed manufacturing systems, use of disposable technologies, design of facility and equipment for containment and ease of cleaning

- Procedural (organizational) controls – e.g., cleaning, personnel flow, environmental monitoring, training

Monitoring systems are important to check the effectiveness of the containment controls.

注)IWGで検討中であり、確定ではない。